How Can We Help?
The evidence supporting the use of oral colchicine is weak although Peyronie’s disease cells react favorable to colchicines in a test tube. The main requirement for the use of any medication as an intralesional agent is that it is safe when given intravenously (as some of the drug will be absorbed from the veins above and below the plaque). Colchicine has never been explored as an intravenous agent and therefore cannot be used intralesionally.